Developer docs
API playgroundTry for free, no card

Search company profiles

Variational AI

Full company profile

uuid00003o1

Namestring
Variational AI
Legal namestring
Variational AI Inc.
Websiteurl
variational.ai
Company typeenum
Private
Founded yearint
2025
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generative AI drug discovery, small molecule design, AI lead optimization, preclinical drug discovery, molecular generation platform
NAICS code1 code
  • Software Publishers513210
SIC code1 code
  • Services-Prepackaged Software7372
Product category
AI Drug Discovery Platform
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Strategic Partnership Payments
TypeLicensing Royalties
Description

Receives upfront payments plus potential milestone payments structured as 'biobucks' from pharmaceutical partnerships. Merck partnership includes undisclosed upfront payment plus milestone payments. No royalties on eventual sales. Partnership value up to $349M USD.

betakit.com
2Collaborative Research Funding
TypeSubscription Recurring
Description

B2B collaborations with biotech and pharma companies for specific drug discovery programs. Includes expanded AI collaborations with companies like Rakovina Therapeutics for ATR inhibitors and other therapeutic targets.

theglobeandmail.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Enki™
Description

Generative AI platform for early-stage drug discovery that generates optimized, synthesis-ready, lead-like compounds tailored to target product profiles. Supports 760 drug targets including kinases, GPCRs, proteases, and other target classes.

variational.ai
Core offering1 text field

Variational AI develops and licenses Enki™, a generative AI foundation model that designs novel, synthesis-ready small-molecule drug candidates de novo. The platform is offered to pharmaceutical and biotechnology partners through direct strategic collaboration agreements, with Enki powering partner lead-generation and lead-optimization workflows spanning kinases, GPCRs, and proximity-based therapeutic modalities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100 AI-generated molecules outperform 1,000,000 molecule high-throughput screening library in benchmark tests
+3 more records
Product overview1 text field

Variational AI offers a single unified platform, Enki™, a generative AI system built on variational autoencoders for small-molecule drug discovery. Enki™ enables direct generation of synthesis-ready lead candidates by jointly optimizing potency, selectivity, ADMET, and synthetic feasibility—eliminating traditional screening libraries and hit-to-lead phases. The platform is offered as a web application (Enki App) accessible to pharma and biotech partners for lead generation and iterative optimization workflows.

Product and service2 records
1Enki™ Generative AI Drug Discovery Platform
CategoryAI Drug Discovery Platform
Description

Generative AI platform for early-stage small-molecule drug discovery. Generates optimized, synthesis-ready, lead-like compounds tailored to a target product profile across kinases, GPCRs, proteases and other target classes, allowing pharma and biotech partners to bypass hit ID and hit-to-lead and move directly into Lead Optimization. Delivered as the Enki web application accessed by partners.

2Enki™ 4
CategoryAI Drug Discovery Platform
Description

Updated release of the Enki platform with broader pre-trained target coverage and support for proximity-based therapeutic modalities. Targeted at the same pharma/biotech partner base to enable generative AI design of degraders, PROTACs and ADC linkers in addition to small molecules.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
13C Therapeutics
Strategic tierMinor/ExploratoryTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

Collaboration to apply Variational AI's Enki platform to ligand design for 3C Therapeutics' proprietary TriCore DAC platform for degrader antibody conjugates. Supported by Innovate BC's Integrated Marketplace program.

variational.ai
Strategic tierMinor/ExploratoryTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

Open-science collaboration to discover novel PRMT6 inhibitors for Spinal and Bulbar Muscular Atrophy (SBMA). Project utilizes AI-driven design, synthetic chemistry, and open science principles to accelerate drug discovery with international partners emphasizing transparency and rapid iteration.

3Rakovina Therapeutics
Strategic tierCore/FlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-08
Description

Expanded collaboration to advance kt-5000 series ATR inhibitors for cancer treatment. Enki applied in iterative optimization loop generating and prioritizing optimized compound designs to progress from early leads toward clinical candidates faster (months vs years). Rakovina retains full control over which candidates advance and owns all compounds developed.

variational.ai
Strategic tierCore/FlagshipTypeStrategic or Co-development PartnerAnnounced on2025-09-23
Description

Two-year development deal potentially worth up to US$349-million. Variational AI uses Enki platform to generate promising molecules for challenging therapeutic targets selected by Merck. Merck receives exclusive rights to develop and commercialize resulting compounds. Variational receives undisclosed upfront payment plus milestone payments ('biobucks') but no royalties on eventual sales. Merck previously invested US$5.5M in Variational's seed extension round.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-18
Description

Second collaboration following successful 2022 SARS-CoV-2 main protease project. Focus on discovering de novo generated selective dual EGFR/FGFR1 inhibitors using Enki platform. Generated 40 molecules fitting target product profile; 19 synthesized with 5 showing dual EGFR+FGFR1 activity. Lead compound: EGFR IC50 = 29nM, FGFR1 IC50 = 175nM.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

End-to-end generative AI drug discovery platform with Pharma.AI suite covering target identification, molecule generation, and clinical development. Competes directly with Enki for enterprise pharma partnerships in small-molecule discovery.

TypeDirect peer
Description

Computational chemistry platform combining physics-based simulation with machine learning for small-molecule drug discovery. Directly comparable in target customers (large pharma) and core offering (in silico lead generation and optimization).

3Iambic Therapeutics
TypeDirect peer
Description

Generative AI platform for small-molecule drug discovery using neural network-based molecule design and multi-parameter optimization. Closest direct competitor in technology approach and pharma partnership model.

TypeDirect peer
Description

AI-driven small-molecule discovery company using convolutional neural networks for structure-based drug design. Targets similar pharma and biotech customer base with comparable lead-generation partnerships.

TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput biology with machine learning across small molecules and biologics. Broader scope than Variational AI but directly comparable in offering AI-driven discovery partnerships to pharma.

6Isomorphic Labs
TypeDirect peer
Description

Alphabet-backed AI drug discovery company applying deep learning to molecular design and protein structure prediction. Direct competitor for large-pharma generative chemistry partnerships.

TypeDirect peer
Description

AI-driven drug discovery platform combining quantum physics, AI, and high-performance computing for small-molecule design. Comparable in offering AI lead-generation partnerships to global pharma.

TypeEmerging player
Description

Generative AI drug discovery platform combining proprietary physics-inspired algorithms with deep learning for small-molecule lead generation. Similar stage and partnership-led GTM motion with pharma.

TypeEmerging player
Description

Generative AI platform for protein and biologics design, adjacent to Variational AI's small-molecule focus but serving overlapping pharma R&D buyers with comparable enterprise partnership model.

TypeEmerging player
Description

Generative biology company using AI to design novel protein therapeutics. Adjacent in generative-AI-for-drug-discovery category with comparable enterprise partnership GTM.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Variational AI

AI Drug Discovery Platformvariational.ai

Variational AI firmographics

Firmographics
Name
Variational AI
Legal name
Variational AI Inc.
Website
https://variational.ai
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Where Variational AI is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Variational AI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Strategic Partnership Payments: Receives upfront payments plus potential milestone payments structured as 'biobucks' from pharmaceutical partnerships. Merck partnership includes undisclosed upfront payment plus milestone payments. No royalties on eventual sales. Partnership value up to $349M USD.
  2. Collaborative Research Funding: B2B collaborations with biotech and pharma companies for specific drug discovery programs. Includes expanded AI collaborations with companies like Rakovina Therapeutics for ATR inhibitors and other therapeutic targets.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Variational AI product offering

Product offering

Core offering

Variational AI develops and licenses Enki™, a generative AI foundation model that designs novel, synthesis-ready small-molecule drug candidates de novo. The platform is offered to pharmaceutical and biotechnology partners through direct strategic collaboration agreements, with Enki powering partner lead-generation and lead-optimization workflows spanning kinases, GPCRs, and proximity-based therapeutic modalities.

Product overview

Variational AI offers a single unified platform, Enki™, a generative AI system built on variational autoencoders for small-molecule drug discovery. Enki™ enables direct generation of synthesis-ready lead candidates by jointly optimizing potency, selectivity, ADMET, and synthetic feasibility—eliminating traditional screening libraries and hit-to-lead phases. The platform is offered as a web application (Enki App) accessible to pharma and biotech partners for lead generation and iterative optimization workflows.

Differentiator

Problem solved

Functional benefit

Brands

  • Enki™: Generative AI platform for early-stage drug discovery that generates optimized, synthesis-ready, lead-like compounds tailored to target product profiles. Supports 760 drug targets including kinases, GPCRs, proteases, and other target classes.

Products and services

  • Enki™ Generative AI Drug Discovery Platform Generative AI platform for early-stage small-molecule drug discovery. Generates optimized, synthesis-ready, lead-like compounds tailored to a target product profile across kinases, GPCRs, proteases and other target classes, allowing pharma and biotech partners to bypass hit ID and hit-to-lead and move directly into Lead Optimization. Delivered as the Enki web application accessed by partners.
  • Enki™ 4 Updated release of the Enki platform with broader pre-trained target coverage and support for proximity-based therapeutic modalities. Targeted at the same pharma/biotech partner base to enable generative AI design of degraders, PROTACs and ADC linkers in addition to small molecules.

Quantifiable outcome

  • 100 AI-generated molecules outperform 1,000,000 molecule high-throughput screening library in benchmark tests
  • +3 more outcomes

Companies that use Variational AI

Customer profile

Named customers6 records

Segments2 records

Ideal customer profiles3 records

Variational AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Variational AI partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor/exploratory, core/flagship and core.

  • 3C Therapeuticsminor/exploratoryStrategic or Co-development Partner · 13 May 2026Collaboration to apply Variational AI's Enki platform to ligand design for 3C Therapeutics' proprietary TriCore DAC platform for degrader antibody conjugates. Supported by Innovate BC's Integrated Marketplace program.
  • Agora Open Science Trustminor/exploratoryStrategic or Co-development Partner · 24 March 2026Open-science collaboration to discover novel PRMT6 inhibitors for Spinal and Bulbar Muscular Atrophy (SBMA). Project utilizes AI-driven design, synthetic chemistry, and open science principles to accelerate drug discovery with international partners emphasizing transparency and rapid iteration.
  • Rakovina Therapeuticscore/flagshipStrategic or Co-development Partner · 8 January 2026Expanded collaboration to advance kt-5000 series ATR inhibitors for cancer treatment. Enki applied in iterative optimization loop generating and prioritizing optimized compound designs to progress from early leads toward clinical candidates faster (months vs years). Rakovina retains full control over which candidates advance and owns all compounds developed.
  • Merckcore/flagshipStrategic or Co-development Partner · 23 September 2025Two-year development deal potentially worth up to US$349-million. Variational AI uses Enki platform to generate promising molecules for challenging therapeutic targets selected by Merck. Merck receives exclusive rights to develop and commercialize resulting compounds. Variational receives undisclosed upfront payment plus milestone payments ('biobucks') but no royalties on eventual sales. Merck previously invested US$5.5M in Variational's seed extension round.
  • Life ChemicalscoreStrategic or Co-development Partner · 18 September 2025Second collaboration following successful 2022 SARS-CoV-2 main protease project. Focus on discovering de novo generated selective dual EGFR/FGFR1 inhibitors using Enki platform. Generated 40 molecules fitting target product profile; 19 synthesized with 5 showing dual EGFR+FGFR1 activity. Lead compound: EGFR IC50 = 29nM, FGFR1 IC50 = 175nM.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Variational AI competitors and assessment

Company assessment

Direct peers

  • Insilico Medicine: End-to-end generative AI drug discovery platform with Pharma.AI suite covering target identification, molecule generation, and clinical development. Competes directly with Enki for enterprise pharma partnerships in small-molecule discovery.
  • Schrödinger: Computational chemistry platform combining physics-based simulation with machine learning for small-molecule drug discovery. Directly comparable in target customers (large pharma) and core offering (in silico lead generation and optimization).
  • Iambic Therapeutics: Generative AI platform for small-molecule drug discovery using neural network-based molecule design and multi-parameter optimization. Closest direct competitor in technology approach and pharma partnership model.
  • Atomwise: AI-driven small-molecule discovery company using convolutional neural networks for structure-based drug design. Targets similar pharma and biotech customer base with comparable lead-generation partnerships.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning across small molecules and biologics. Broader scope than Variational AI but directly comparable in offering AI-driven discovery partnerships to pharma.
  • Isomorphic Labs: Alphabet-backed AI drug discovery company applying deep learning to molecular design and protein structure prediction. Direct competitor for large-pharma generative chemistry partnerships.
  • XtalPi: AI-driven drug discovery platform combining quantum physics, AI, and high-performance computing for small-molecule design. Comparable in offering AI lead-generation partnerships to global pharma.

Emerging players

  • Aqemia: Generative AI drug discovery platform combining proprietary physics-inspired algorithms with deep learning for small-molecule lead generation. Similar stage and partnership-led GTM motion with pharma.
  • Cradle Bio: Generative AI platform for protein and biologics design, adjacent to Variational AI's small-molecule focus but serving overlapping pharma R&D buyers with comparable enterprise partnership model.
  • Generate Biomedicines: Generative biology company using AI to design novel protein therapeutics. Adjacent in generative-AI-for-drug-discovery category with comparable enterprise partnership GTM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Variational AI social profiles

Digital presence

Variational AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Variational AI leadership team

Management profile

Number of profiles

Profiles8 records

Variational AI funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Variational AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Variational AI

What does Variational AI do?

Variational AI develops and licenses Enki™, a generative AI foundation model that designs novel, synthesis-ready small-molecule drug candidates de novo. The platform is offered to pharmaceutical and biotechnology partners through direct strategic collaboration agreements, with Enki powering partner lead-generation and lead-optimization workflows spanning kinases, GPCRs, and proximity-based therapeutic modalities.

Is Variational AI a public or private company?

Variational AI is a private company. It is classified as venture growth investor backed and is currently operating.

When was Variational AI founded?

Variational AI was founded in 2025. It employs 11 to 50 people.

Where is Variational AI based?

Variational AI is headquartered in Vancouver, Canada, in the North America region.

How does Variational AI make money?

Two revenue lines are on record. Strategic Partnership Payments are the primary driver. The others are collaborative Research Funding.

Who are Variational AI's main competitors?

Direct peers on record are Insilico Medicine, Schrödinger, Iambic Therapeutics, Atomwise, Recursion Pharmaceuticals, Isomorphic Labs and XtalPi. Emerging players are Aqemia, Cradle Bio and Generate Biomedicines.

Does Variational AI have an API?

No public API is recorded for Variational AI.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Financial PostRakovina Therapeutics Secures Exclusivity on Optimized kt-5000 Lead Profile from Variational AIRakovina Therapeutics secured exclusivity on its optimized kt-5000 lead profile from Variational AI, using the Enki platform to advance the ATR program. The amendment provides additional optimization cycles at no extra cost, aiming to preserve capital and strengthen its position toward nominating a development candidate and engaging pharmaceutical partners.TechcouverHow 3C Therapeutics Is Applying AI to Accelerate Drug Discovery3C Therapeutics, a Vancouver-based biotech firm, is developing advanced cancer therapies with its proprietary TriCore platform and is exploring how generative AI can accelerate drug discovery. The company is partnering with Variational AI to evaluate AI-designed drug candidates, supported by the British Columbia government through the Integrated Marketplace program. The project aims to shorten the development timeline for new cancer treatments while strengthening B.C. 's life sciences sector.The Streetwise ReportsCancer Drug Developer Shifts 70% of Spending to Research as AI Pipeline ProgressesRakovina Therapeutics reported Q1 2026 research and development expenses of CA$1,031,556, up from CA$885,594, while general and administrative expenses fell to CA$443,986. The company's R&D spending represented about 70% of total operating expenses, and it completed a CA$1.0 million convertible debenture financing. The company also presented preclinical data at the AACR meeting and advanced its AI-powered oncology pipeline.BioSpaceRakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate UpdateRakovina Therapeutics reported Q1 2026 results with R&D expenses up 16% to $1.03M and a net loss of $1.68M, down 23% year-over-year. G&A fell 64% to $444K, and cash rose to $586K after a $1M convertible debenture. The company plans to advance partnership discussions with its AI-discovered oncology pipeline.BioSpaceRakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate UpdateRakovina Therapeutics reported Q4 and FY2025 results with a net loss of $8.68 million and a working capital deficit of $2.15 million. The company advanced its AI-driven DDR inhibitor pipeline, with kt-5000 lead optimization and kt-3283 LNP testing underway. It also closed $1 million in convertible debenture financing and restructured existing debt.GlobeNewswireRakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate UpdateRakovina Therapeutics reported Q4 2025 net loss of $1.89M and full-year loss of $8.68M, with a working capital deficit of $2.15M. The company closed $1M in convertible debenture financing and restructured $1.59M in existing debentures. It plans to advance its DDR inhibitor pipeline and pursue pharmaceutical partnerships.BioSpaceRakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual MeetingRakovina Therapeutics presented preclinical data on two AI-designed cancer drug programs at AACR 2026. The dual ATR-mTOR inhibitor showed in vivo efficacy in a prostate tumor model with better tolerability than a reference compound, and a lipid nanoparticle formulation of kt-3283 was successfully characterized. The company plans to advance best-in-class leads toward IND-enabling studies.Financial PostVariational AI Releases Enki 4: Major Update to Foundation Model for Small-Molecule Drug DiscoveryVariational AI announced the release of Enki 4, a major update to its generative AI platform for small-molecule drug discovery, in Vancouver, Canada. The platform's pre-trained target coverage expanded from 592 to 760 drug targets, a 28% increase, while also extending its application to degraders, PROTACs, glues, and novel payload design for antibody drug conjugates. The company stated that Enki 4 enables biotech partners to generate novel leads that would not have been discovered using traditional methods, with the goal of eliminating hit identification and hit-to-lead stages.BcbusinessIs B.C. building its own AI future—or someone else’s?British Columbia is home to over 700 AI companies that are successfully selling world-class applied AI solutions globally, including a potential $349 million deal between Vancouver's Variational AI and U.S. pharma giant Merck for AI-powered drug discovery, yet the province faces criticism for slow domestic AI adoption and self-imposed limits on data centre expansion due to electricity rationing policies. Provincial officials argue the 2026 electricity limits are designed to keep hydro rates low and prioritize job-producing projects, while opposition critics and tech founders warn the restrictions could force B.C. companies to commercialize their innovations elsewhere and leave the province as a late adopter of technology developed in its own backyard. B.C. aims to double tech-sector employment to 400,000 over the next decade and has established a K-12 AI advisory committee, though industry leaders say faster immigration pathways, housing cost reductions, and government procurement reform are needed to retain local talent and companies.